ProCE Banner Activity

Phase III APACT Trial: Adjuvant nab-Paclitaxel Plus Gemcitabine vs Gemcitabine in Patients With Surgically Resected Pancreatic Adenocarcinoma

Slideset Download
Conference Coverage

In the phase III APACT trial, adding nab-paclitaxel to adjuvant gemcitabine did not significantly prolong DFS by independent review but improved OS in an interim analysis in resected pancreatic cancer.

Released: June 04, 2019

Expiration: June 02, 2020

No longer available for credit.

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Astellas Seattle Genetics

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Novartis Pharmaceuticals Corporation

Puma Biotechnology, Inc.

Taiho Oncology Inc

Tesaro